Tags: Fusidate

Giardia: Clinical Syndromes

After ingestion of G lamblia cysts, 5-15% of patients will have asymptomatic cyst passage, and 25-50% of patients will have diarrhea. From 35% to 70% of these patients will have no evidence of infection. The three manifestations of infection include asymptomatic cyst passage, self-limited diarrhea, and chronic diarrhea with associated malabsorption and weight loss. Factors related to each of these manifestations are unknown but are believed to be related to specific host factors, parasite load, and virulence variation among G lamblia isolates. ACUTE GIARDIASIS Clinical Findings Signs and Symptoms After ingestion of cysts, an incubation period of 3-20 days exists before symptom onset. At the time of presentation, patients have generally […]

Fusidic Acid

Drug Nomenclature International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish): Synonyms: Ácido fusídico; Acidum Fusidicum; Acidum Fusidicum Hemihydricum; Fucidinsyra; Fusídico, ácido; Fusidiinihappo; Fusidinsyra; Fuzidinsav; Fuzido rūgštis; Kyselina fusidová hemihydrát; SQ-16603 BAN: Fusidic Acid USAN: Fusidic Acid INN: Fusidic Acid [rINN (en)] INN: Ácido fusídico [rINN (es)] INN: Acide Fusidique [rINN (fr)] INN: Acidum Fusidicum [rINN (la)] INN: Фэузидовая Кислота [rINN (ru)] Chemical name: ent-16α-Acetoxy-3β-dihydroxy-4β,8β,14α-trimethyl-18-nor-5β,10α-cholesta-(17Z)-17(20),24-dien-21-oic acid hemihydrate Molecular formula: C31H48O6,1/2H2O =525.7 CAS: 6990-06-3 (anhydrous fusidic acid) ATC code: D06AX01; D09AA02; J01XC01; S01AA13 Read code: y00kx [Eye]; y012G Pharmacopoeias. In Europe. European Pharmacopoeia, 6th ed., 2008 and Supplements 6.1 and 6.2 (Fusidic Acid). An antimicrobial substance produced by the […]